Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Advanced Diagnostics 2016

Rajani Kanth Vangala's Biography



Rajani Kanth Vangala, Director of Research, Thrombosis Research Institute

Dr. Rajani Kanth Vangala, finished his Ph.D in Human Biology specializing on Hematolo-oncology from Department of Medicine III, Ludwig Maximillians University, Munich, Germany followed by post doctoral research at Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden working on developing Karolinska-Institutet microarray chip and novel computational algorithms for microarray data analysis. After his post doctoral work, he joined Department of Hematology, Imperial College London, UK as senior researcher and worked on stem cell therapy models and DNA repair mechanisms in acute and chronic myeloid leukemias. He was also awarded the technology entrepreneur fellowship for business management studies by Tanaka Business School, Imperial College London. Further to this experience, he started a company named Innovo Biologicals Pvt. Ltd. focusing on molecular diagnostics and sold it to venture capital company and joined Institute of Bioinformatics and Applied Biotechnology, Bangalore as faculty before moving to Thrombosis Research Institute (TRI), Bangalore. He is presently the Director of Research and his work focuses on identification of biomarkers for translation to drug development and clinical utility using integrative translational informatics, genomics, proteomics and nanotechnology

Rajani  Kanth Vangala Image

Integrative Translational Big-Data Analysis to Identify Predictive Biomarkers and Drug-Target Interactions

Thursday, 26 May 2016 at 17:00

Add to Calendar ▼2016-05-26 17:00:002016-05-26 18:00:00Europe/LondonIntegrative Translational Big-Data Analysis to Identify Predictive Biomarkers and Drug-Target InteractionsAdvanced Diagnostics 2016 in BengaluruBengaluruSELECTBIOenquiries@selectbiosciences.com

In this talk, development of a novel approach of integrating clinical data of more than 11,000 subjects’ data suffering from Heart disease and stroke with genomics and proteomics research outcomes will be discussed. Along, it will deliberate about biomarkers identification for improved risk prediction and diagnosis. Furthermore, it will highlight how using network analysis, drug-target interactions can be developed for improved drug development. Finally, it will mention that how these approaches are now also applied in other diseases for novel biomarkers and drug targets.


Add to Calendar ▼2016-05-26 00:00:002016-05-27 00:00:00Europe/LondonAdvanced Diagnostics 2016Advanced Diagnostics 2016 in BengaluruBengaluruSELECTBIOenquiries@selectbiosciences.com